Paola A. Ascierto, MD, medical oncologist, director of Melanoma Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori “Fondazione G. Pascal,” discusses results of a phase Ib/II dose-escalation study evaluating triple combination therapy with encorafenib, binimetiinib, and ribociclib (Kisquali) in patients with <em>BRAF V600</em> solid tumors and melanoma.
Paola A. Ascierto, MD, medical oncologist, director of Melanoma Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori “Fondazione G. Pascal,” discusses results of a phase Ib/II dose-escalation study evaluating triple combination therapy with encorafenib, binimetiinib, and ribociclib (Kisquali) in patients withBRAF V600solid tumors and melanoma.
Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Read More